Michael J. Mitten

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

Tilman Oltersdorf, Steven W. Elmore, Alexander R. Shoemaker et al. · Nature · 2005 · 3.4K citations

Medicine, Molecular Biology, Oncology +14

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

Andrew J. Souers, Joel D. Leverson, Erwin R. Boghaert et al. · Nature Medicine · 2013 · 3K citations

Medicine, Oncology, Pharmacology +10

ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor

Christin Tse, Alexander R. Shoemaker, Jessica Adickes et al. · Cancer Research · 2008 · 2K citations · Full text

Medicine, Oncology, Pharmacology +16

Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy

Joel D. Leverson, Darren C. Phillips, Michael J. Mitten et al. · Science Translational Medicine · 2015 · 541 citations · Full text

Medicine, Oncology, Pharmacology +14

Discovery of a Potent and Selective BCL-X _L Inhibitor with <i>in Vivo</i> Activity

Zhi‐Fu Tao, Lisa Hasvold, Le Wang et al. · ACS Medicinal Chemistry Letters · 2014 · 331 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +10